Glucotrack, Inc.

RUTHERFORD, N.J. & LA JOLLA, Calif. – Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (Nasdaq: GCTK), today announced that it will partner with Pepperdine E2B™ (Education to Business) to engage students in its ai2 Pipeline™ initiative during the upcoming academic year. The collaboration is intended to provide students with hands-on experience evaluating real-world biopharmaceutical opportunities...

RUTHERFORD, N.J. & LA JOLLA, Calif. – Glucotrack, Inc. (NASDAQ: GCTK) (“Glucotrack” or the “Company”) today announced the pricing of a “best efforts” public offering of 169,388 shares of common stock at a price of $2.04 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase up to...

Innovate GBM becomes the first external organization to engage the ai² Division on a fee-for-service basis to identify brain tumor therapeutic assets for potential licensing and development RUTHERFORD, N.J. & LA JOLLA, Calif. & LOS ANGELES – Lōkahi Therapeutics™ Inc., a subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), today announced that Innovate GBM, a 501(c)(3) nonprofit...

RUTHERFORD, N.J. & LA JOLLA, Calif. – Lōkahi Therapeutics™ today issued a strategic corporate update highlighting progress in its LT-100 development program, expansion of its ai² platform, and priorities for advancing and monetizing differentiated therapeutic assets. A Clear View of Who We Are A Message From Our CEO, Erik Emerson Good morning. I’m Erik Emerson,...

RUTHERFORD, N.J. & LA JOLLA, Calif. – Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (Nasdaq: GCTK), today announced that The University of Alabama’s Culverhouse College of Business will continue its participation in the ai² Pipeline division for the upcoming academic year. The renewed collaboration extends a hands-on program in which students evaluate real-world biopharmaceutical business...

RUTHERFORD, N.J. & LA JOLLA, Calif. – Glucotrack, Inc. (NASDAQ: GCTK) (“Glucotrack” or the “Company”) today announced definitive agreements for convertible notes with an aggregate principal amount of approximately $11.5 million, including approximately $4.5 million of new cash investment and approximately $4.5 million of existing notes being rolled over, with the aggregate principal amount reflecting...

ai² Pipeline™, ai² Talent™, and ai² Accelerator™ create potential revenue-generating opportunities while strengthening Lōkahi’s therapeutic development platform. RUTHERFORD, N.J., & LA JOLLA, Calif. – Lōkahi Therapeutics™ Inc., a subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), today announced the expansion of its ai² platform into three dedicated business divisions: ai² Pipeline™, ai² Talent™, and ai² Accelerator™. The...

RUTHERFORD, N.J., & LA JOLLA, Calif. – Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (Nasdaq: GCTK), today announced a collaboration with San Diego State University’s (SDSU) Fowler College of Business, expanding the ai² Futures Lab™ and strengthening Lōkahi’s growing network of partner academic institutions. The partnership with SDSU furthers Lōkahi’s work to identify and evaluate...

1-for-15 reverse stock split to become effective as of the opening of trading on August 31, 2026 RUTHERFORD, N.J. & LA JOLLA, Calif. – Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a healthcare technology and biopharmaceutical company operating Lōkahi Therapeutics™, today announced that it will effect a 1-for-15 reverse stock split (the “Reverse Stock...

One year of work focused on one goal: manufacturing clinical material to enable once-weekly dosing RUTHERFORD, N.J. & LA JOLLA, Calif. – Lōkahi Therapeutics™ Inc., a subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), today announced that it has started its initial Good Manufacturing Practice (GMP) manufacturing campaign for LT-100 (pure honeybee venom), the Company’s lead development...